Psychedelic therapy could offer a new path for managing depression in Parkinson's

It is a fascinating time to be looking at the horizon of Parkinson's care. My own interest peaked recently when the headlines shifted from "mushrooms" as a hobby to "psychedelics" as a serious medical priority. With the Executive Order on Accelerating Medical Treatments for Serious Mental Illness signed in April 2026 in the US, and the FDA moving to expedite reviews for breakthrough therapies, we are no longer just dreaming about "someday." We are seeing a structural shift in how researchers like Dr Ellen Bradley from University of California, San Francisco can study these compounds for people with Parkinson's. However, before we start looking for tickets to Mexico to try peyote, let’s keep our feet on the ground. As Dr Bradley explained in her recent webinar with PD Connect, the transition from "illegal substance" to "medical therapy" is built on careful science, not street use. Dr Bradley started by addressing what she calls the Parkinson's iceberg. While everyone sees the motor symptoms like tremors and stiffness above the water, there is a massive section underneath that is often invisible. This includes sleep problems, fatigue, and especially depression. Depression affects about half of all people with Parkinson’s and is actually a stronger predictor of quality of life than how a person moves. Even though we have a buffet of treatments available, such as behavioural activation and standard medications, they simply do not work for everyone. This gap in care, combined with the new legislative freedom to conduct research, is exactly why the medical community is so excited about the potential of psilocybin. The science behind this interest revolves around a concept called neuroplasticity. Researchers describe psychedelics as neuroplastogens, which essentially means they are substances capable of inducing a rapid increase in the brain's ability to adapt and rewire itself. During the webinar, Dr Bradley showed how neurons exposed to psilocybin actually grow more branches, or dendrites, which increases the opportunities for neurons to communicate. In Parkinson's, where these connections are often taking a hit, psilocybin may open a window for adaptive learning, allowing the brain to bypass the thinking ruts that keep people stuck in depressive loops. It is vital to distinguish between casual use and the clinical psilocybin therapy being researched at UCSF. This is a package deal that involves synthetic psilocybin—not natural mushrooms, which are too unpredictable in strength—combined with intensive talk therapy. The process includes preparation sessions to build trust, an all-day supervised session that can last seven hours, and integration sessions afterward to process the intense emotions and perceptions that occur. The UCSF pilot study with twelve participants found that this approach was safe, with no serious adverse events, and remarkably, the mood improvements lasted for weeks or even months after just one or two doses. Despite the excitement, we must remain witty and grounded regarding the risks. Dr Bradley highlighted that because Parkinson's involves the autonomic system, psilocybin can act as a bit of a stress test for the heart and blood pressure. There is also the concern regarding hallucinations, as people with Parkinson’s are already more vulnerable to psychosis, and we don't want to make those symptoms worse. Furthermore, we still have a lot to learn about how these compounds interact with common medications like Levodopa. As the research expands to Yale University and moves into larger trials, the goal is to see if we can safely leverage this window of plasticity to improve mental health. While we are in a season of exploration fueled by these new laws, the current gold standard for rewiring the brain remains physical exercise and big movements. We are essentially looking for ways to give the brain a better pathway, ensuring that when we do open that window of plasticity, we are instilling good habits rather than maladaptive ones. It is a promising horizon, but for now, we stay firmly committed to the work that supports health right here and right now.